ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease

References

• Mort M, Ivanov D, Cooper DN, et al. A meta-analysis of nonsense mutations causing human genetic disease. Hum Mutat. 2008 Aug;29(8):1037–1047.
   PubMed Web of Science ®Google Scholar
• Schuller AP, Green R. Roadblocks and resolutions in eukaryotic translation. Nat Rev Mol Cell Biol. 2018 Aug;19(8):526–541.
   PubMed Web of Science ®Google Scholar
• Mendell JT, Dietz HC. When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell. 2001 Nov 16;107(4):411–414.
   PubMed Web of Science ®Google Scholar
• Celik A, Kervestin S, Jacobson A. NMD: at the crossroads between translation termination and ribosome recycling. Biochimie. 2015 Jul;114:2–9.
   PubMed Web of Science ®Google Scholar
• Quinton PM. Cystic fibrosis: lessons from the sweat gland. Physiology (Bethesda). 2007 Jun;22:212–225.
   PubMed Web of Science ®Google Scholar
• Hardin DS. GH improves growth and clinical status in children with cystic fibrosis – a review of published studies. Eur J Endocrinol. 2004 Aug;151(Suppl 1):S81–5.
   PubMedGoogle Scholar
• O’Malley CA. Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist. Respir Care. 2009 May;54(5):641–657.
   PubMed Web of Science ®Google Scholar
• De Lisle RC. Pass the bicarb: the importance of HCO3- for mucin release. J Clin Invest. 2009 Sep;119(9):2535–2537.
   PubMed Web of Science ®Google Scholar
• Strausbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. Clin Chest Med. 2007 Jun;28(2):279–288.
   PubMed Web of Science ®Google Scholar
• Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. N Engl J Med. 2015 Apr 16;372(16):1574–1575.
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Skach W, Baker O, et al. A multifunctional aqueous channel formed by CFTR. Science. 1992 Nov 27;258(5087):1477–1479.
   PubMed Web of Science ®Google Scholar
• McCague AF, Raraigh KS, Pellicore MJ, et al. Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis. Am J Respir Crit Care Med. 2019 May 1;199(9):1116–1126.
   PubMed Web of Science ®Google Scholar
• Kalatzis V, Cherqui S, Antignac C, et al. Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter. Embo J. 2001 Nov 1;20(21):5940–5949.
   PubMed Web of Science ®Google Scholar
• Elmonem MA, Veys KR, Soliman NA, et al. Cystinosis: a review. Orphanet J Rare Dis. 2016 Apr;22(11):47.
   Google Scholar
• Shotelersuk V, Larson D, Anikster Y, et al. CTNS mutations in an American-based population of cystinosis patients. Am J Hum Genet. 1998 Nov;63(5):1352–1362.
   PubMed Web of Science ®Google Scholar
• David D, Princiero Berlingerio S, Elmonem MA, et al. Molecular basis of cystinosis: geographic distribution, functional consequences of mutations in the CTNS gene, and potential for repair. Nephron. 2019;141(2):133–146.
   PubMed Web of Science ®Google Scholar
• Thoene JG, Oshima RG, Crawhall JC, et al. Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo. J Clin Invest. 1976 Jul;58(1):180–189.
   PubMed Web of Science ®Google Scholar
• Gahl WA, Balog JZ, Kleta R. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intern Med. 2007 Aug 21;147(4):242–250.
   PubMed Web of Science ®Google Scholar
• Brodin-Sartorius A, Tete MJ, Niaudet P, et al. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int. 2012 Jan;81(2):179–189.
   PubMed Web of Science ®Google Scholar
• Kandasamy J, Atia-Glikin D, Shulman E, et al. Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations. J Med Chem. 2012 Dec 13;55(23):10630–10643.
   PubMed Web of Science ®Google Scholar
• Pokrovskaya V, Nudelman I, Kandasamy J, et al. Aminoglycosides redesign strategies for improved antibiotics and compounds for treatment of human genetic diseases. Methods Enzymol. 2010;478:437–462.
   PubMed Web of Science ®Google Scholar
• Shulman E, Belakhov V, Wei G, et al. Designer aminoglycosides that selectively inhibit cytoplasmic rather than mitochondrial ribosomes show decreased ototoxicity: a strategy for the treatment of genetic diseases. J Biol Chem. 2014 Jan 24;289(4):2318–2330.
   PubMed Web of Science ®Google Scholar
• Bidou L, Bugaud O, Belakhov V, et al. Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells. RNA Biol. 2017 Mar 4;14(3):378–388.
   PubMed Web of Science ®Google Scholar
• Crawford DK, Alroy I, Sharpe N, et al. ELX-02 generates protein via premature stop codon read-through without inducing native stop codon read-through proteins. J Pharmacol Exp Ther. 2020 Aug;374(2):264–272.
   PubMed Web of Science ®Google Scholar
• Xue X, Mutyam V, Tang L, et al. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol. 2014 Apr;50(4):805–816.
   PubMed Web of Science ®Google Scholar
• Brasell EJ, Chu LL, Akpa MM, et al. The novel aminoglycoside, ELX-02, permits CTNSW138X translational read-through and restores lysosomal cystine efflux in cystinosis. PLoS One. 2019;14(12): e0223954.
   PubMed Web of Science ®Google Scholar
• Garg SK, Verma SP, Uppal RP. Pharmacokinetics of gentamicin following single-dose parenteral administration to goats. Br Vet J. 1995 Jul-Aug;151(4):453–458.
   PubMedGoogle Scholar
• Leubitz A, Frydman-Marom A, Sharpe N, et al. Safety, tolerability, and pharmacokinetics of single ascending doses of ELX-02, a potential treatment for genetic disorders caused by nonsense mutations, in healthy volunteers. Clin Pharmacol Drug Dev. 2019 Nov;8(8):984–994.
   PubMed Web of Science ®Google Scholar
• Leubitz A, Sharpe N, Maier G, et al. Pharmacokinetics, safety, and tolerability of multiple ascending doses of ELX-02 in healthy volunteers, a potential treatment for cystic fibrosis caused by nonsense mutations. North American Cystic Fibrosis Conference. Nashville, TN 2019.
   Google Scholar
• Williams G, Leubitz A, Preston R, et al. An open label, single dose, parallel-group study to evaluate the effects of renal impairment on the pharmacokinetics of ELX-02. American society of nephrology (ASN) kidney week. Washington DC. J Am Soc Nephrol. 2019;10:210.
   Google Scholar
• Dabrowski M, Bukowy-Bieryllo Z, Zietkiewicz E. Translational readthrough potential of natural termination codons in eucaryotes–The impact of RNA sequence. RNA Biol. 2015;12(9):950–958.
   PubMed Web of Science ®Google Scholar
• Xue X, Mutyam V, Thakerar A, et al. Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences. Hum Mol Genet. 2017 Aug 15;26(16):3116–3129.
   PubMed Web of Science ®Google Scholar
• Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001 Jun;163(7):1683–1692.
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Famini C, Blau H, et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):860–865.
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349(15):1433–1441.
   PubMed Web of Science ®Google Scholar
• Prayle A, Smyth AR. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Curr Opin Pulm Med. 2010 Nov;16(6):604–610.
   PubMed Web of Science ®Google Scholar
• O’Sullivan ME, Perez A, Lin R, et al. Towards the prevention of aminoglycoside-related hearing loss. Front Cell Neurosci. 2017;11:325.
   PubMed Web of Science ®Google Scholar
• Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008 Aug 30;372(9640):719–727.
   PubMed Web of Science ®Google Scholar
• Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med. 2010 Nov 15;182(10):1262–1272.
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J. 2011 Jul;38(1):59–69.
   PubMed Web of Science ®Google Scholar
• Kerem E, Konstan MW, De Boeck K, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014 Jul;2(7):539–547.
   PubMed Web of Science ®Google Scholar
• Konstan MW, VanDevanter DR, Rowe SM, et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren confirmatory trial in cystic fibrosis (ACT CF). J Cyst Fibros. 2020 Jul;19(4):595–601.
   PubMed Web of Science ®Google Scholar